keyword
MENU ▼
Read by QxMD icon Read
search

Liposomal amphotericin b formulation

keyword
https://www.readbyqxmd.com/read/29785613/neuroinfections-caused-by-fungi
#1
REVIEW
Katarzyna Góralska, Joanna Blaszkowska, Magdalena Dzikowiec
BACKGROUND: Fungal infections of the central nervous system (FIs-CNS) have become significantly more common over the past 2 decades. Invasion of the CNS largely depends on the immune status of the host and the virulence of the fungal strain. Infections with fungi cause a significant morbidity in immunocompromised hosts, and the involvement of the CNS may lead to fatal consequences. METHODS: One hundred and thirty-five articles on fungal neuroinfection in PubMed, Google Scholar, and Cochrane databases were selected for review using the following search words: "fungi and CNS mycoses", CNS fungal infections", "fungal brain infections", " fungal cerebritis", fungal meningitis", "diagnostics of fungal infections", and "treatment of CNS fungal infections"...
May 21, 2018: Infection
https://www.readbyqxmd.com/read/29760126/experimental-amphotericin-b-deoxycholate-formulations-for-pulmonary-aspergillosis-efficacy-biodistribution-and-nephrotoxicity
#2
Alicia López-Sánchez, Alba Pérez-Cantero, Carlos Torrado-Salmerón, Adela Martin-Vicente, Víctor García-Herrero, María Ángeles González-Nicolás, Alberto Lázaro, Alberto Tejedor, Santiago Torrado-Santiago, Juan José García-Rodríguez, Javier Capilla, Susana Torrado
An experimental micellar formulation of amphotericin B (AMB) with sodium deoxycholate (DCH), AMB:DCH 1:1.5, was obtained and characterized to determine its aggregation state and particle size. Biodistribution, nephrotoxicity and efficacy against pulmonary aspergillosis in a murine model were studied and compared to the liposomal commercial amphotericin B after intravenous administration. The administration of 5 mg/kg AMB:DCH 1:1.5 presented 2.8-fold higher lung concentrations (18.125 ± 3.985 μg/g, after 6 daily doses) and lower kidney exposure (0...
May 14, 2018: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29737887/current-approaches-to-visceral-leishmaniasis-treatment-in-solid-organ-transplant-recipients
#3
Wanessa Trindade Clemente, Paulo Henrique Orlandi Mourão, Jose María Aguado
The increasing number of transplants performed worldwide and the growing global mobility with migration and travel to and from developing countries and tropical areas are bringing new challenges for the management of transplant infectious diseases, previously less commonly seen, such as Leishmaniasis. However, in this scenario there is a lack of information and the current knowledge is based on a few studies. The selection of the most appropriate treatment depends on various factors, such as patient profile, Leishmania species, disease extent, drug availability, concomitant infections and previous treatments...
May 8, 2018: Expert Review of Anti-infective Therapy
https://www.readbyqxmd.com/read/29686150/evaluation-of-amphotericin-b-lipid-formulations-for-treatment-of-severe-coccidioidomycosis
#4
Ritam Sidhu, David B Lash, Arash Heidari, Piruthiviraj Natarajan, Royce H Johnson
BACKGROUND: Patients with severe coccidioidomycosis infections are often treated with either amphotericin-B lipid complex (ABLC) or liposomal amphotericin-B (L-AmB). Outcomes data with these agents in severe coccidioidomycosis are currently lacking. The purpose of this study is to evaluate the efficacy and toxicity of ABLC and L-AmB in treating severe coccidioidomycosis. METHODS: A retrospective, pre-post study design was employed. Chart reviews were completed from 01/01/2005 to 12/31/2014 for all patients who received lipid-based amphotericin B...
April 23, 2018: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29673889/comparative-efficacy-toxicity-and-biodistribution-of-the-liposomal-amphotericin-b-formulations-fungisome-%C3%A2-and-ambisome-%C3%A2-in-murine-cutaneous-leishmaniasis
#5
Gert-Jan Wijnant, Katrien Van Bocxlaer, Vanessa Yardley, Andy Harris, Mo Alavijeh, Rita Silva-Pedrosa, Sandra Antunes, Isabel Mauricio, Sudaxshina Murdan, Simon L Croft
Fungisome® (F), a liposomal amphotericin B (AmB) product, is marketed in India as a safe and effective therapeutic for the parasitic infection visceral leishmaniasis. Its potential in the treatment of cutaneous leishmaniasis (CL), a disfiguring form of the disease affecting the skin, is currently unknown. Here, we report the evaluation of the efficacy of F in the Leishmania major BALB/c murine model of CL, including a head-to-head comparison with the standard liposomal AmB formulation AmBisome® (A). Upon intravenous administration at dose levels of 5, 10 and 15 mg/kg of body weight (on days 0, 2, 4, 6 and 8), F showed clear signs of toxicity (at 15 mg/kg), while A did not...
April 12, 2018: International Journal for Parasitology, Drugs and Drug Resistance
https://www.readbyqxmd.com/read/29607918/-a-case-of-histoplasmosis-with-chronic-basilar-meningitis-diagnosed-relatively-early
#6
Asako Onda, Shinji Miyagawa, Taku Gomi, Tetuya Horino, Katuhiko Kamei, Hiroshi Yaguchi
A 41-year-old man left for Mexico in May 2015. Right pulmonary nodule was detected at a health examination in May 2016, and he subsequently showed headache and slight fever. Contrast-enhanced magnetic resonance imaging of the brain revealed basilar meningitis, so he was admitted to our hospital. We considered imported mycosis due to his travel history to Mexico. We diagnosed histoplasmosis based on the presence of antibodies against Histoplasma in both serum and cerebrospinal fluid. Symptoms almost completely recovered with a liposomal formulation of amphotericin B...
March 31, 2018: Rinshō Shinkeigaku, Clinical Neurology
https://www.readbyqxmd.com/read/29596219/efficacy-and-safety-of-echinocandins-for-the-treatment-of-invasive-candidiasis-in-children-a-meta-analysis
#7
Magdalini Tsekoura, Maria Ioannidou, Zoi-Dorothea Pana, Anna-Bettina Haidich, Charalampos Antachopoulos, Elias Iosifidis, George Kolios, Emmanuel Roilides
BACKGROUND: Echinocandins are recommended for the treatment of suspected or confirmed invasive candidiasis (IC) in adults. Less is known about the use of echinocandins for the management of IC in children. The aim of this study was to investigate the overall efficacy and safety of echinocandin class in neonatal and pediatric patients with IC. METHODS: PubMed, Cochrane Central, Scopus and Clinical trial registries were searched up to July 27, 2017. Eligible studies were randomized trials (RCTs) that evaluated the efficacy and safety of any echinocandin versus agents of other antifungal classes for the treatment of IC in pediatric patients...
March 24, 2018: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/29595679/central-nervous-system-histoplasmosis-multicenter-retrospective-study-on-clinical-features-diagnostic-approach-and-outcome-of-treatment
#8
MULTICENTER STUDY
Joseph Wheat, Thein Myint, Ying Guo, Phebe Kemmer, Chadi Hage, Colin Terry, Marwan M Azar, James Riddell, Peter Ender, Sharon Chen, Kareem Shehab, Kerry Cleveland, Eden Esguerra, James Johnson, Patty Wright, Vanja Douglas, Pascalis Vergidis, Winnie Ooi, John Baddley, David Bamberger, Raed Khairy, Holenarasipur R Vikram, Elizabeth Jenny-Avital, Geetha Sivasubramanian, Karen Bowlware, Barbara Pahud, Juan Sarria, Townson Tsai, Maha Assi, Satish Mocherla, Vidhya Prakash, David Allen, Catherine Passaretti, Shirish Huprikar, Albert Anderson
Central nervous system (CNS) involvement occurs in 5 to 10% of individuals with disseminated histoplasmosis. Most experience has been derived from small single center case series, or case report literature reviews. Therefore, a larger study of central nervous system (CNS) histoplasmosis is needed in order to guide the approach to diagnosis, and treatment.A convenience sample of 77 patients with histoplasmosis infection of the CNS was evaluated. Data was collected that focused on recognition of infection, diagnostic techniques, and outcomes of treatment...
March 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29365355/comprehensive-drug-utilization-review-in-neonates-liposomal-amphotericin-b
#9
REVIEW
Chirlie Silver, Sara Rostas
OBJECTIVES: This drug utilization evaluation aims to review current evidence on safety and efficacy of using liposomal amphotericin B (LAMB) in newborns with candidiasis, and compare it to the conventional preparation. Conventional amphotericin B deoxycholate (DAMB) is more commonly used in newborns, but dose-limiting adverse effects may compromise its efficacy. This review will examine the advantages and disadvantages of liposomal amphotericin B and define its place in current practice...
March 2018: Journal of Pharmacy and Pharmacology
https://www.readbyqxmd.com/read/29352486/adverse-effects-of-amphotericin-b-in-children-a-retrospective-comparison-of-conventional-and-liposomal-formulations
#10
Eden C Andrew, Nigel Curtis, Ben Coghlan, Noel Cranswick, Amanda Gwee
AIMS: Lipid formulations of amphotericin B, rather than conventional amphotericin (c-amB), are increasingly used despite limited data comparing these preparations in children. Data on the incidence of adverse effects with amphotericin B at standard doses are scarce. This study aimed to compare the adverse effects associated with standard doses of c-amB and liposomal amphotericin (l-amB) in children. METHODS: Children admitted to the Royal Children's Hospital Melbourne and treated with c-amB or l-amB between January 2010 and September 2013 were included...
May 2018: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29305017/potential-usefulness-of-early-potassium-supplementation-for-preventing-severe-hypokalemia-induced-by-liposomal-amphotericin-b-in-hematologic-patients-a-retrospective-study
#11
Naoto Okada, Momoyo Azuma, Masaki Imanishi, Yoshito Zamami, Yasushi Kirino, Toshimi Nakamura, Kazuhiko Teraoka, Masahiro Abe, Keisuke Ishizawa
PURPOSE: Liposomal amphotericin B (L-AMB) is an essential antifungal agent for patients with hematologic diseases; however, the drug causes severe hypokalemia at a high frequency. Meanwhile, there is little evidence regarding the risk factors for L-AMB-induced severe hypokalemia, and the prevention protocol has not been established. The goal of this study was to identify the risk factors related to severe hypokalemia induced by L-AMB in hematologic patients. METHODS: Seventy-eight hematologic patients with a first administration of L-AMB were enrolled in the study...
February 2018: Clinical Therapeutics
https://www.readbyqxmd.com/read/29194382/liposomal-and-deoxycholate-amphotericin-b-formulations-effectiveness-against-biofilm-infections-of-candida-spp
#12
Célia F Rodrigues, Mariana Henriques
BACKGROUND: candidiasis is the primary fungal infection encountered in patients undergoing prolonged hospitalization, and the fourth leading cause of nosocomial bloodstream infections. One of the most important Candida spp. virulence factors is the ability to form biofilms, which are extremely refractory to antimicrobial therapy and very difficult to treat with the traditional antifungal therapies. It is known that the prophylaxis or treatment of a systemic candidiasis are recurrently taken without considering the possibility of a Candida spp...
December 1, 2017: Pathogens
https://www.readbyqxmd.com/read/29138100/amphotericin-b-for-treatment-of-visceral-leishmaniasis-systematic-review-and-meta-analysis-of-prospective-comparative-clinical-studies-including-dose-ranging-studies
#13
REVIEW
C Rodrigo, P Weeratunga, S D Fernando, S Rajapakse
OBJECTIVES: To evaluate the evidence for use of different formulations of amphotericin B (AmB), minimum effective dose for each formulation and its comparative efficacy against other drugs in achieving definitive cure of visceral leishmaniasis. METHODS: This systematic review and meta-analysis included following data sources: PubMed, Embase, Scopus, Web of Science and CINAHL. Controlled prospective clinical trials (randomized or nonrandomized, including dose-ranging studies) conducted between 1996 and 2017 with at least one treatment group receiving AmB were included (published data only)...
November 11, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/28988704/fungal-infections-of-the-central-nervous-system-in-small-animals-clinical-features-diagnosis-and-management
#14
REVIEW
R Timothy Bentley, Amanda R Taylor, Stephanie A Thomovsky
Small animal mycoses vary geographically. Different clinical presentations are seen in animals with infection of the central nervous system (CNS), including multifocal meningoencephalomyelitis, intracranial lesions that accompany sinonasal lesions, rapidly progressive ventriculitis, or solitary granuloma of the brain or spinal cord. Systemic, nasal, or extraneural clinical signs are common but, especially in granuloma cases, do not always occur. Surgery may have a diagnostic and therapeutic role in CNS granuloma...
January 2018: Veterinary Clinics of North America. Small Animal Practice
https://www.readbyqxmd.com/read/28946803/anti-biofilm-activity-of-a-sophorolipid-amphotericin-b-niosomal-formulation-against-candida-albicans
#15
Farazul Haque, Mohammad Sajid, Swaranjit Singh Cameotra, Mani Shankar Battacharyya
Sophorolipids (SLs) have gained interest in the pharmaceutical industries due to their anti-microbial, anti-adhesive and anti-biofilm properties. In the present study, the production of SL was increased by using low-cost media components. The potential of a SL-based niosomal formulation of amphotericin B (AmB) was determined against biofilm of the opportunistic fungal pathogen Candida albicans. In-house prepared SL-AmB niosomes were characterized by different microscopic techniques. The mean entrapment efficiency of AmB within SL-AmB niosome was 63...
October 2017: Biofouling
https://www.readbyqxmd.com/read/28928478/biomimetically-engineered-amphotericin-b-nano-aggregates-circumvent-toxicity-constraints-and-treat-systemic-fungal-infection-in-experimental-animals
#16
Qamar Zia, Owais Mohammad, Mohd Ahmar Rauf, Wasi Khan, Swaleha Zubair
Biomimetic synthesis of nanoparticles offers a convenient and bio friendly approach to fabricate complex structures with sub-nanometer precision from simple precursor components. In the present study, we have synthesized nanoparticles of Amphotericin B (AmB), a potent antifungal agent, using Aloe vera leaf extract. The synthesis of AmB nano-assemblies (AmB-NAs) was established employing spectro-photometric and electron microscopic studies, while their crystalline nature was established by X-ray diffraction...
September 19, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28925873/silver-nanoparticles-with-high-loading-capacity-of-amphotericin-b-characterization-bactericidal-and-antifungal-effects
#17
Victoria Leonhard, Roxana Valeria Alasino, Adrián Muñoz, Dante Miguel Beltramo
The purpose of this study was to evaluate the most appropriate conditions to generate silver nanoparticles (AgNPs) loaded with a potent antimycotic drug like amphotericin B (AmB), characterize the physicochemical properties, and also evaluate the cytotoxic effect and biological activity of these new nanostructures as a potential nanocarrier for hydrophobic drugs. It was determined that the optimal molar ratio between Ag and AmB is 1/1 given the uniformity of size around 1750 nm of the nanoparticles generated as well as their strongly negative ζ potential of -27 mV, a condition that favors repulsions between AgNPs and inhibiting their aggregation...
September 18, 2017: Current Drug Delivery
https://www.readbyqxmd.com/read/28874072/liposomal-formulations-in-the-pharmacological-treatment-of-leishmaniasis-a-review
#18
Vanessa Ortega, Selma Giorgio, Eneida de Paula
Conventional chemotherapy for leishmaniasis includes considerably toxic drugs and reports of drug-resistance are not uncommon. Liposomal encapsulated drugs appear as an option for the treatment of leishmaniasis, providing greater efficacy for the active and reducing its side effects by promoting superior tissue absorption, favouring drug penetration into the macrophages, and retarding its clearance from the site of action. In this paper, a review on the advances achieved with liposome-based anti-leishmaniasis drug delivery systems is presented...
September 2017: Journal of Liposome Research
https://www.readbyqxmd.com/read/28865757/a-cell-impedance-based-real-time-in-vitro-assay-to-assess-the-toxicity-of-amphotericin-b-formulations
#19
Jean Menotti, Alexandre Alanio, Aude Sturny-Leclère, Sandrine Vitry, Félix Sauvage, Gillian Barratt, Stéphane Bretagne
Aerosolized liposomal amphotericin B (L-AmB) has been investigated as prophylaxis against invasive aspergillosis. However, the clinical results are controversial and some trials suggest that toxicity could be a limitation for wider use. Our aim was to assess the dynamics of cell toxicity induced in a human alveolar epithelial cell line (A549) after exposure to L-AmB (50 to 400μg/ml) or amphotericin B deoxycholate (D-AmB; 50 to 200μg/ml) by monitoring real-time A549 cell viability using an impedance-based technology...
November 1, 2017: Toxicology and Applied Pharmacology
https://www.readbyqxmd.com/read/28815733/comparison-of-the-pharmacokinetic-profiles-of-two-different-amphotericin-b-formulations-in-healthy-dogs
#20
B Bingöl, T Bakirel
This study was conducted to compare the pharmacokinetic profiles of conventional (Fungizone® ) and liposomal amphotericin B (AmBisome® ) formulations in order to predict their therapeutic properties, and evaluate their potential differences in veterinary treatment. For this purpose, twelve healthy mixed breed dogs received both drugs at a dose of 0.6 mg/kg by intravenous infusion over a 4-min period in a total volume of 40 ml. Blood samples were collected at 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 48, 72 and 96 hr after dosing, and concentrations of drug in plasma were determined by high-performance liquid chromatography (HPLC)...
February 2018: Journal of Veterinary Pharmacology and Therapeutics
keyword
keyword
101730
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"